Monkeypox

This Phase 2 study will test a new mpox vaccine called MVA-SIBP in 180 people aged 2 to 45 in Kinshasa, DRC. Participants will receive two doses of either a low or high dose of the new vaccine, or a licensed vaccine (MVA-BN) for comparison. The goal is to check safety and how wel…

This large study will test the LC16m8 mpox vaccine in nearly 12,000 people aged one year and older in the Democratic Republic of Congo. Researchers want to see if the vaccine can prevent mpox disease and monitor its safety. Participants will receive the vaccine as part of the gov…

This study tests a drug called Sintilimab, which is normally used for cancer, to see if it can help people with HIV who have infections that won't go away with standard treatment. The drug works by 'waking up' exhausted immune cells. Fifty adults with HIV and a hard-to-treat infe…

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This study will check how well three new rapid tests detect mpox virus compared to a standard lab test. Researchers will use about 80 stored skin swab samples from Uganda. The goal is to see if these quick, portable tests are accurate enough for use in places without full labs.

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This study looks at how well the body remembers mpox after an infection. Researchers will measure antibodies and special immune cells in 60 people who had mpox. The goal is to understand how long protection might last and how strong it is.

This study in Guinea will follow about 992 people to understand how long the mpox virus stays in the body after infection, how it spreads to close contacts, and how well the MVA-BN vaccine protects against infection and disease. Researchers will collect samples and track particip…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…

This observational study will follow 95 adults who receive a booster dose of the MVA-BN vaccine against mpox. Researchers will collect blood and other samples over two years to measure antibody and immune cell responses. The goal is to understand how long the booster's protection…